Hello traders and investors! Over 55,000 traders have registered for The Leap paper trading competition. The assets in the competition include SPX500, JP225, and DE30. This analysis may help in making the right decision. Weekly Timeframe Analysis: All three indices interacted on the daily timeframe with the level at the base of the last buyer's impulse on...
The Leap competition is live and so is Pinchpips. Focusing on the behemoth of OANDA:WTICOUSD and $OANDA:XAUUSD. Not typical markets but testing swing zones on the instruments to check efficacy on a daily TF. SZ are set for OANDA:WTICOUSD but price action determines entry Currently ranked 2716. www.tradingview.com
Trade Idea: Long Japan 255 at 30677.3 Entry: 30677.3 Stop Loss (SL): 27869.0 Take Profit (TP): 41133.8 Dollar-Cost Averaging (DCA) Zone: 28625.0 Terminology Explained Demand Zone: A price area where buying interest is expected to be strong, potentially causing the price to rise. In this trade, the demand zone at 30677.3 suggests an opportunity to enter a long...
Hi traders and investors! More than 13,000 traders have registered for The Leap paper trading competition. One of the assets of the competition is XAUUSD. Perhaps this analysis will help you make the right decision (the SPX500 analysis is available in the linked idea). In a related idea, XAUUSD predicted that if the buyer defends the $2378 - $2383 range, then...
🔉Sound on!🔉 Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
🔉Sound on!🔉 Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
Thank you as always for watching my videos. Please feel free to like, share, and comment on this post!
Filecoin could be one of the winners of the next bull-run! Potential 7x growth in the coming months Targets: 9,8 $ 21,2 $ 53,5 $ BINANCE:FILUSDT CRYPTOCAP:TOTAL2 ! Not an advice - DYOR !
This price forecast is purely based on technical analysis of the current setup. I guess people are drinking a lot? We've had an extremely long stretch of green - which is a stale green light - 11 days in a row of green & 6 weeks straight of green - that hasn't happened since 2017 - it looks like the stock is trying to breakout on the weekly chart, but it looks...
Past few days indicate a possible leap over night. We'll see by the last 15-20 minutes of close... Estimated new open at 396-397. Feel free to share thoughts and ideas to help me improve. AMEX:SPY
We see a demand base at $345-$280 blocking the price to drop as a result of the falling wedge caused by the Q3-4 transition. After the stock jumps above the wedge (breaking the trend, see red circle), we see it respecting & hovering around the 382 support established and respected at the following dates (10th December '20, 16th November '20, 10th November '20,...
Around 3.7M pumped in silver this week. Entered 3 32C 3/31 Leap. Inverse H&S as well.
A new, super aggressive bullish channel has been formed and I will closely observe its top and bottom levels. In the short run I think we are all set to go parabolic, however this - as all parabolic moves (apart from TSLA) - is bound to be broken eventually, the question is only when. I might reap my LEAP rewards once the channel is broken and re-enter later, but...
NASDAQ:TSLA Tesla stock ($TSLA) is at a critical entry point @ $1488. Do you want to take the Leap?
Leap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly. As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent. The technical's are now aligning with some key dates with a potential short...
Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a...